Beijing SL Pharmaceutical Co Ltd

Beijing SL Pharmaceutical Co Ltd


Company description

Beijing ShuangLu Pharmaceutical Co Ltd, well known as "SL PHARM", is a high biotechnology-pharmaceutical company, mainly engaged in developing and marketing genetic engineering drugs. The company, founded in December 1994, was originally named as "Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd.", and changed the name to "Beijing ShuangLu Pharmaceutical Co., Ltd." in 1998. It became a Joint-Stock Company Limited in August 2000 and was listed in Chinese Stock Exchange in 2004. SL Pharm is located in Haidian District, Beijing, China. Registration capital of the company is CNY 248 million, and total asset is about CNY 600 million.

The plant is located in Beijing Badachu High-tech Zone, which occupies 12,000 square meters, and workshops are well equipped with GMP authentication production lines. Annual production capacity of the manufacturer reaches 20 millions of pharmaceutical injections, and 200 millions of oral solid pharmaceutical products (tablets). All products have got GMP Authentication issued by Chinese State Food & Drug Administration (SFDA). Management is performed according to the requirements of international GMP standards from workshops, equipments, raw or auxiliary materials, packing materials to production, quality and hygiene.

The staff of SL Pharm is more than 200 in total, 81% of whom have BS or above degree, and 93% have qualified technical expertise. General Manager, Dr. Mingbo Xu, is a biopharmacologist, an expert in bioengineering technology and molecular biology. As an excellent scientist, Dr. Xu is awarded Government Special Subsidy for his outstanding contribution.

In the last ten years, our company developed and marketed more than 40 kinds of new drugs. Among these drugs, 2 are certificated as the 1st class drugs and 11 as the 2nd class drugs. In addition, more than 20 kinds of new products are in the registration pipeline. Our leading products "Li Sheng Su" (recombinant human granulocyte colony-stimulating factor for injection, G-CSF injection), "Mai Ge Er" (recombinant human interleukin-11 for injection, rhIL-11) and "Xin Ji Er" (recombinant human 125Ala interleukin-2 for injection, 125Ala IL-2) won the title of "National Key New drugs", all of which were obtained the 2nd award of "Science and Technology Progress" and "Excellent New Product Award" authenticated by Beijing Municipal Government. G-CSF and 125Ala IL-2 also won the title of "Beijing Famous Brand" in 2002. Our product "Fu Ji Fu"(lyophilized recombinant human basic fibroblast growth factor for external use, rh-bFGF)was listed in both of "National Torch Program" and "National Important New Product Project" and won the 1st award of "Beijing Science and Technology Progression" and the 2nd "National Science and Technology Progression". Since 2000, our company has been commented as "Excellent Credit Enterprise" (known as "AAA grand-enterprise") by National Ministry of Bank. We hope to provide more effective and cheaper medicines for human being and to provide present work environment for our staff. By carrying out this strategy, SL Pharm has made fruitful achievements in financing & capital expansion, technology innovation and market management.

Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; North America; Africa; Central/South America
Primary business activity Manufacturer
Affiliated categories: Finished Dosage Forms More

Recently at

20 jun 2017

CPhI & PMEC China 2017

June 20 - 22, 2017 Shanghai, China We were at stand E2G69 See our Exhibitor Profile   See full Exhibitor List

Categories affiliated with Beijing SL Pharmaceutical Co Ltd

Beijing SL Pharmaceutical Co Ltd

Contact information




View all contact information